Tue, Oct 21, 2014, 11:35 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

  • tjnelis tjnelis Jul 23, 2014 7:49 PM Flag


    just as it was in the testing for ruxo, with MF, the outcome will be more than likely be approved for severe cases, and to those intolerant to HU. So it is asked why then is this hurting the stock? A couple of reason come to mind, the stock is still trading in a death cross pattern, secondly it is a phase III trial that missed on endpoints. What management was trying to do here, after hopeful approval from the FDA, was to say again to the fda look at the RELIEF study it works on the MILD PV cases. How much money and works have been spent, and now it is another phase 2 or 3 trial to go back and see if they can still get it approved for mild PV. DID not INcyte go all through this once already in the approval for MF, the answer is yes, so why did they think it would now work for PV???? They sure presented to investors that they thought it would be? I think that pretty much gives you why it will be down. oh, the ceo says it is undervalued in the 60's, insiders have sold massive amounts of holdings....earnings will be a miss, and oh how nice it is to hear the sNDA has been filed on a PHASE 3 (RELIEF) missing its ENDPOINTS, good use of PR

    SortNewest  |  Oldest  |  Most Replied Expand all replies
52.44+1.65(+3.25%)Oct 21 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.